Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

Mise à jour : Il y a 4 ans
Référence : NCT02302066

Femme et Homme

Extrait

The purpose of this study is to assess the humoral immune responses to Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in a subset of healthy participants between 2 and <18 years of age living in dengue endemic countries.


Critère d'inclusion

  • Dengue fever

Liens